FindTrial
Sign In

Randomised, Double-Blind, Placebo Controlled, Cross Over Trial of a Parenteral Modified Cobratoxin in Adrenomyeloneuropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN48334111
Enrollment
Unknown
Registered
2005-03-10
Start date
2000-03-10
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenomyeloneuropathy (AMN) Nervous System Diseases

Interventions

Modified cobratoxin (0.25 mg) administered subcutaneously (sc) twice daily for 6 months versus placebo injections.

Sponsors

ReceptoPharm Inc. (USA)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female age =18 years 2. Diagnosis of AMN either biochemically or genetically 3. Have some motor disability that affects their gait 4. Willing and able to provide written informed consent 5. Willing and able to comply with study procedures

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration.—

Secondary

MeasureTime frame
Not provided at time of registration.—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026